Continuous cell lines have become a preferred choice for numerous pharmaceutical and biotech companies when testing drug efficacy. This shift has resulted in a reduced reliance on gnotobiotic animals like mice, rabbits, and monkeys for research purposes. The extended shelf life and easy preservation of these cell lines through cryopreservation and lyophilization techniques make them advantageous for research and development (R&D) activities in the biotech and pharmaceutical sectors. In 2014, the Department of Pharmaceutical Sciences and Bio Manufacturing Research Institute and Technology Enterprises (BRITE) reported a substantial investment of around USD 1.3 billion in new pharmaceuticals for drug discovery through cell line culture.
While 3D cell culture models are gaining traction in research, cell lines are expected to maintain their relevance in the market due to various capabilities. These include interactions between different cell types, the integration of flow, the establishment of barrier tissues, better simulation of conditions in a living organism, reduced dependence on animal models, and a more realistic approach to growing and treating tumor cells. Cell culture biosensors contribute to biomedical and bioanalytical applications, enabling early detection and chronic disease management, along with environmental monitoring.
The cell line culture technique serves as a crucial bridge between in-vitro and in-vivo culturing processes, finding applications in diverse fields such as cancer cell biology, drug discovery, and stem cell research. According to an updated report from North Carolina Central University in 2014, cell line culture biosensors are particularly valuable for anticancer drug screening due to their ability to conduct multiplex analyses of different drugs and cancer cells.
Market leaders like ECACC and ATCC hold substantial shares, serving as exclusive suppliers of authentic cell lines. Their extensive product portfolios, covering cell lines, media, and equipment globally, contribute to their dominance in the market. The increasing utilization of cell lines across various applications has also opened doors for new entrants in the market. Compared to the organ culture model, the cell line culture model stands out as a better option, providing more accurate results in less time. Over the past decade, the cell line culture model has been extensively utilized for research purposes, showcasing its significance and effectiveness in advancing scientific understanding.
February 2024
For the first time ever, the revolutionary spontaneously immortalized bovine myoblast cell line known as PROFUSE-B8 has been formally introduced, and it is now available for licensing. In announcing its official debut, ProFuse Technology is glad to share the news. This recent achievement, which marks a significant milestone in the field of farmed meat, has resulted in the introduction of a paradigm shift in the efficient growth of muscle tissue that is rich in protein.
The PROFUSE-B8 cell line, which has been the subject of significant study and testing over the course of a full two-year period, provides cultured meat manufacturers with a solid and robust foundation for the establishment of scalable, repeatable, and cost-competitive production processes. This has been accomplished by testing and researching the cell line over the course of two years. It is important to note that B8 is able to do this without using any method that includes genetic alteration. This ensures that it is in complete accordance with the preferences and consent of customers.
Its revolutionary features are complimented by the fact that, when taken with the PROFUSE-S1 muscle differentiation media supplement, the synthesis of muscle tissue is speed up, which results in increased productivity in a shorter length of time. This is a significant advantage.
ProFuse Technology is 100% committed to advancing the cultured meat business by providing cutting-edge solutions for the production of muscle-related goods. This commitment is steadfast. At the same time, the company is making significant progress toward the development of other muscle production-optimized cell lines that are tailored to the unique requirements of chicken, hog, lamb, and fish for specialized purposes.
According to Dr. Tamar Eigler-Hirsh, Chief Technology Officer and Co-Founder of ProFuse Technology, in a statement, "We are thrilled to introduce PROFUSE-B8 as a transformative solution for the cultivated meat industry." "Our dedication to innovation and productivity is evident in the development of this breakthrough cell line, and we are confident it will shape the future of cell based protein production."
Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017.
Immortalized Cell Line Industry Developments
In January 2024,Thermo Fisher Scientific Launched new Gibco™ Advanced DMEM/F12 media optimized for immortalized cell lines, claiming improved growth and performance.
In September2023,Lonza Group AG Announced partnership with CStone Pharmaceuticals to optimize and manufacture immortalized cell lines for CAR-T cell therapy development.
Americas
North America
US
Canada
South America
Europe
Western Europe
Germany
UK
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Asia-Pacific
China
Japan
India
South Korea
Rest of Asia-Pacific
Middle East & Africa
Middle East
Africa
Intended Audience
Research and development (R&D) companies
Government research institutes
Academic institutes and universities
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)